Antifungal activity of anidulafungin, a product of Aspergillus nidulans, against Aspergillus nidulans

International Journal of Antimicrobial Agents

Volumn 33, Issue 3, 2009, Pages 285-286

  Hof, H ^a   Dietz, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anidulafungin; Aspergillus nidulans; Growth inhibition

Indexed keywords

ANIDULAFUNGIN; ECHINOCANDIN B;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS NIDULANS; DILUTION; DRUG ACTIVATION; DRUG SENSITIVITY; FETAL CALF SERUM; FUNGAL STRAIN; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS NIDULANS; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS;

EID: 60249096908     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.08.022     Document Type: Article

References (15)

1. Benz F., Knuesel F., Nuesch J., Treichler H., Voser W., Nyfeler R., et al. Echinocandin B, a new polypeptide antibiotic from Aspergillus nidulans var. echinulatus: isolation and components [in German]. Helv Chim Acta 57 (1985) 2459-2477
2. Hodges R.L., Kelkar H.S., Xuei X., Skatrud P.L., Keller N.P., Adams T.H., et al. Characterization of an echinocandin B-producing strain blocked for sterigmatocystin biosynthesis reveals a translocation in the stcW gene of the aflatoxin biosynthetic pathway. J Ind Microbiol Biotechnol 25 (2000) 333-341
3. De Lucca A.J., and Walsh T.J. Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 43 (1999) 1-11
4. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
5. Laverdiere M., Labbé A.C., Restieri C., Rotstein C., Heyland D., Madger S., et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care 22 (2007) 245-250
6. Oakley K.L., Moore C.B., and Denning D.W. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 42 (1998) 2726-2730
7. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 43 (2005) 5425-5427
8. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008) 150-156
9. Wiederhold N.P., Najvar L.K., Bocanegra R., Molina D., Olivo M., and Graybill J.R. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 51 (2007) 1616-1620
10. Panagopoulou P., Filioti J., Farmaki E., Maloukou A., and Roilides E. Filamentous fungi in a tertiary care hospital: environmental surveillance and susceptibility to antifungal drugs. Infect Control Hosp Epidemiol 28 (2007) 60-67
11. Messer S.A., Kirby J.T., Sader H.S., Fritsche T.R., and Jones R.N. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 54 (2004) 1051-1056
12. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. M38-A. Wayne, PA: CLSI; 2002.
13. Zhanel G.G., Saunders D.G., Hoban D.J., and Karlowsky J.A. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother 45 (2001) 2018-2022
14. Ernst E.J., Roling E.E., Petzold C.R., Keele D.J., and Klepser M.E. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 46 (2002) 3846-3853
15. Pfaller M.A. Anidulafungin: an echinocandin antifungal. Expert Opin Investig Drugs 13 (2004) 1183-1197